Poseida's Allogeneic CAR-T Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma
• P-BCMA-ALLO1, an allogeneic CAR-T therapy from Poseida Therapeutics, demonstrates promising results in heavily pretreated multiple myeloma patients.
• The Phase 1/1b trial showed a 91% overall response rate in patients receiving enhanced lymphodepletion, indicating improved efficacy.
• No graft-versus-host disease was observed, and cytokine release syndrome was mostly low grade, highlighting a favorable safety profile.
• P-BCMA-ALLO1 offers a potential off-the-shelf alternative to autologous CAR-T therapies, addressing the unmet need for immediate treatment options.
Poseida Therapeutics, Inc.
Posted 5/5/2022